ATRC

Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($38.42); post-transaction value based on August 05, 2026 market close ($39.34). What was the scale of the transaction relative to the insider's total position?Yuen reduced her direct equity stake by 20%, bringing her total beneficial ownership to 14,015 shares. How does the execution price compare to recent market levels?The 3,500 shares were sold at a weighted average price of $38.42, which was slightly below the $39.34 market close on the day of the transaction. Shares have shown relative stability, priced at $39.49 as of the August 6 market close. What is the company's current financial profile in the healthcare sector?AtriCure is a medical device company with a market capitalization of $2.0 billion. The firm reported trailing twelve-month revenue of $569.6 million, maintaining a focus on specialized cardiac treatment technologies. AtriCure designs, manufactures, and markets specialized medical devices for the surgical treatment of cardiac tissue and intercostal nerves, including radiofrequency ablation technologies such as the Isolator Synergy Clamps and multifunctional surgical pens like the MAX Pen that enable surgeons to diagnose and treat cardiac arrhythmias. The company generates revenue through the sale of proprietary ablation and surgical devices to hospitals and surgical centers, leveraging its specialized technology platform to address unmet clinical needs in cardiac surgery and arrhythmia management. AtriCure serves cardiac surgeons and surgical teams across the United States, Europe, Asia, and other international markets, with its products integrated into standard surgical protocols for atrial fibrillation and other cardiac conditions. AtriCure is a focused medical device company with a $2.0 billion market capitalization and $569.6 million in TTM revenue, positioning itself as a specialized provider of cardiac surgical solutions. The company maintains a differentiated product portfolio centered on radiofrequency ablation technology, which provides competitive advantages in the treatment of cardiac arrhythmias and related conditions. With a global distribution network spanning multiple continent, AtriCure has established itself as a significant player in the cardiac surgery device market. Two AtriCure directors sold on the same day, and Yuen's cut ran deeper in percentage terms, clearing a fifth of her direct stake in one go. That kind of matching timing might mean a trading window opened after earnings and a couple of board members stepped through it together, not that either soured on the company.More importantly for long-term investors, the company gave them a solid quarter to sell into. AtriCure grew second-quarter revenue 13% to $154 million, and its appendage-management franchise, built around its AtriClip devices for reducing stroke risk, rose 14% on newer Mini versions. CEO Michael Carrel pointed to growth "fueled by continued adoption" across its franchises, and gross margin widened to 77%, all of which helped management lift its full-year outlook. Shares have recovered quite a bit since June lows of around $25, surging more than 60%, and they’re up about 15% over the past year. After a strong quarter, whether the latest momentum continues will depend a lot on continued execution — much more than share sales like this one. Before you buy stock in AtriCure, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AtriCure wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 7, 2026. Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors was originally published by The Motley Fool

AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth potential. The company reported its Q2 FY26 earnings on July 23, delivering revenue of $153.6 million and an adjusted EPS of $0.18. With healthy growth and a step up in profitability, the company’s revenue and adjusted EPS exceeded the consensus estimates by $1.79 million and $0.16, respectively. This marks a solid 800% EPS beat. The highlight of the quarter was net income of $9 million, compared with a net loss of $6.2 million in Q2 of 2025.  Thanks to the continued adoption in the pain management franchise, appendage management franchise, and open ablation franchise, the company delivered $27 million in adjusted EBITDA. Copyright: nimon / 123RF Stock Photo Gross margin increased to 77.2% in Q2 2026, up 270 basis points from the Q2 2025 level, primarily driven by product innovation, geographic mix, and efficiencies. The company’s US business was up 14% YoY, with worldwide revenue growing 13%. While the appendage management franchise grew 14% in the quarter, driven by AtriClip FLEX-Mini and PRO-Mini products, pain management saw another fantastic quarter, delivering 27% worldwide growth. This was due to the adoption of CryoSphere MAX. Management expects continued gross margin benefits in the second half, despite a small headwind from its new manufacturing facility, which is aimed at enhancing the current manufacturing capability and capacity. The key catalyst is post-operative AFib, the healthcare spending for which surpasses $2 billion annually. Through the BoxX-NoAF clinical study, AtriCure, Inc. (NASDAQ:ATRC) will be able to capitalize on this opportunity. The company is on track to enroll all 960 patients by the year-end, even ahead of its original plan. The second most powerful catalyst is its LeAAPS clinical trial, which focuses on cardiac surgery patients without AFib. This will help broaden the company’s addressable market. Together, these two studies will provide AtriCure, Inc. (NASDAQ:ATRC) with complementary paths for label expansion in the cardiac surgery market. The company is also engaged in increasing the adoption of the Encompass clamp. The new STS quality metric on concomitant AFib treatment is anticipated to enhance the adoption even further. With that said, management sees $602 million-$610 million in revenue for the year. The company also raised its adjusted EBITDA guidance to nearly $85 million-$89 million and an EPS of roughly $0.05-$0.13 for the full-year 2026. At its current price, ATRC appears reasonably valued. The company trades at a forward P/B of 2.95x, below the sector median of 3.47x. The valuation becomes even more compelling when we consider the company’s long-term potential. As the company capitalizes on the billion-dollar opportunity, many big names are expected to compete. For instance, on June 29, Edwards Lifesciences Corporation (NYSE:EW) received FDA approval for its Ecliptis left atrial appendage exclusion system, which will directly compete with AtriCure’s AtriClip platform. Earlier, the company was facing competition from Medtronic plc (NYSE:MDT), as the latter rolled out the Penditure LAA exclusion system in November 2023. However, analysts at Canaccord Genuity believe the launch will have minimal impact on the company’s AtriClip business, which remains well-positioned in the surgical left atrial appendage closure market. Similarly, Medtronic’s launch had little impact on the company’s product. The company also experiences international softness, particularly in the U.K. and Germany. While this has the potential to weigh on future results, management is optimistic that Encompass adoption will offset the impact of CryoSphere probe losing reimbursement in that market. According to Insider Monkey’s database, the hedge fund ownership dipped marginally to 27 funds in Q1 2026 from 28 in the previous quarter. The relatively small change suggests that institutional investors have largely maintained their exposure to the company amid its growth momentum. Several notable hedge funds maintain positions in ATRC, including Hood River Capital Management and Marshall Wace LLP. Overall, the company is a compelling long-term investment case, driven by the growing adoption of the Encompass clamp and its potential to capitalize on the post-operative AFib opportunity. With management raising its adjusted EBITDA guidance and the stock trading below the sector median, ATRC appears reasonably valued relative to its growth potential. However, investors should continue to monitor the competitive landscape and international headwinds. While we acknowledge the potential of ATRC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.

This article first appeared on GuruFocus. Worldwide Revenue: $154 million, growth of 13% year over year. US Revenue: $125.6 million, increase of 13.6% year over year. Adjusted EBITDA: Over $27 million. Net Income: $9 million, compared to a net loss of $6.2 million in the prior year. Gross Margin: 77.2%, approximately 270 basis points higher than the previous year. Pain Management Revenue: $27.1 million, growth of 27.8% year over year. Open Ablation Revenue: $40.9 million, up 12.1% year over year. Appendage Management Revenue: $51.6 million, growth of 14.4% year over year. International Revenue: $28 million, up 9.6% on a reported basis. Cash and Investments: $167.8 million, with $22 million in cash generated during the quarter. Full-Year Revenue Guidance: $602 million to $610 million, reflecting growth of 12.5% to 14% over 2025. Full-Year Adjusted EBITDA Guidance: $85 million to $89 million. Full-Year Earnings Per Share Guidance: $0.05 to $0.13, adjusted earnings per share of $0.24 to $0.32. Is ATRC fairly valued? Test your thesis with our free DCF calculator. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AtriCure Inc (NASDAQ:ATRC) reported a solid second-quarter revenue of $154 million, marking a 13% growth year-over-year. The company achieved over $27 million in adjusted EBITDA and $9 million in net income, indicating strong profitability improvements. The BoxX-NoAF clinical study has surpassed the 50% enrollment mark, with over 500 patients enrolled, ahead of schedule. The pain management franchise experienced a 27% worldwide growth, driven by the adoption of cryoSPHERE MAX. AtriCure Inc (NASDAQ:ATRC) raised its full-year adjusted EBITDA outlook to approximately $85 million to $89 million, reflecting confidence in continued financial performance. The minimally invasive ablation business remains under pressure due to market focus on PFA catheters. International revenue growth was slower, with a 9.6% increase on a reported basis and 7.1% on a constant-currency basis. The UK market continues to face challenges, with sequentially flat performance due to reimbursement issues. The company anticipates ongoing pressure within MIS ablation and certain international markets. There is a potential risk of competition in the appendage management market, with new entrants possibly impacting market share. Q: Can you discuss the impact of new competitors entering the appendage management market and how AtriCure plans to maintain its market position? A: Michael Carrel, President and CEO, explained that the entry of larger companies validates the market opportunity. AtriCure is ahead with superior products, ongoing innovation, and a strong clinical compendium. The company has invested in clinical trials and maintains a robust field and education team to support its leadership position. Q: What is driving the growth in the pain management business, and can it become AtriCure's second-largest franchise? A: Michael Carrel noted that growth is driven by underpenetrated thoracotomy procedures and expanding into sternotomy and limb amputation areas. The cryoSPHERE MAX probe has significantly contributed to this growth, and the franchise has potential to become a major revenue driver. Q: How sustainable is the profitability seen in this quarter, and what are the expectations for adjusted EBITDA in the coming years? A: Angela Wirick, CFO, highlighted strong gross margins and controlled operating expenses as key drivers. The company is ahead of its long-range plan and expects to maintain profitability while funding growth opportunities, aiming for competitive margins by 2030. Q: Can you provide an update on the international markets, particularly the UK and Asia Pacific? A: Angela Wirick mentioned that Asia Pacific markets showed recovery, while the UK and Germany faced challenges. The company is optimistic about international market rebound and has incorporated these pressures into its guidance for the year. Q: What are the expectations for the BoxX-NoAF trial, and what is the timeline for FDA submission and approval? A: Michael Carrel stated that the trial is ahead of schedule, with data expected by mid-2027. The trial is a PMA product, and the company plans to submit to the FDA after data presentation, with approval anticipated about a year later. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

AtriCure (ATRC) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.8%. EPS of $0.18 for the same period compares to -$0.02 a year ago. The reported revenue represents a surprise of +1.39% over the Zacks Consensus Estimate of $151.5 million. With the consensus EPS estimate being $0.03, the EPS surprise was +500%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: United States Revenue- Pain management: $27.06 million versus the three-analyst average estimate of $24.91 million. The reported number represents a year-over-year change of +27.8%. International Revenue- Pain management: $2.38 million versus $2.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change. United States Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $73.97 million compared to the $71.95 million average estimate based on three analysts. The reported number represents a change of +13% year over year. International Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $15.64 million versus $16.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6% change. United States Revenue- Total: $125.59 million versus the three-analyst average estimate of $122.88 million. The reported number represents a year-over-year change of +13.6%. International Revenue- Appendage management: $12.37 million compared to the $12.57 million average estimate based on three analysts. The reported number represents a change of +14.5% year over year. United States Revenue- Open ablation: $40.89 million compared to the $40.9 million average estimate based on three analysts. The reported number represents a change of +12.1% year over year. International Revenue- Open ablation: $11.24 million compared to the $11.39 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year. United States Revenue- Minimally invasive ablation: $6.03 million versus $6.14 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.1% change. International Revenue- Minimally invasive ablation: $2.02 million versus $2.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.8% change. United States Revenue- Appendage management: $51.61 million versus $50.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change. International Revenue- Total: $28.02 million versus the three-analyst average estimate of $28.7 million. The reported number represents a year-over-year change of +9.6%. View all Key Company Metrics for AtriCure here>>> Shares of AtriCure have returned +18.5% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AtriCure, Inc. (ATRC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in AtriCure, Inc.? Here are five stocks we like better. AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP profitability. Adjusted EBITDA jumped 78% year over year to $27.3 million, while net income improved to $9 million from a $6.2 million loss a year earlier. Growth was led by pain management, appendage management and open ablation, while minimally invasive ablation remained under pressure. Pain management was the fastest-growing franchise, up 27% worldwide, driven by CryoSphere MAX and early traction for CryoXT. Management raised full-year guidance, now expecting 2026 revenue of $602 million to $610 million and adjusted EBITDA of $85 million to $89 million. The company also highlighted advancing BoxX-NoAF and LeAAPS trials, which could support future label expansion and long-term growth. AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation. The medical device company generated worldwide revenue of $153.6 million, up 12.8% on a reported basis and 12.4% in constant currency from the second quarter of 2025, according to Chief Financial Officer Angela Wirick. U.S. revenue rose 13.6% to $125.6 million, while international revenue increased 9.6% on a reported basis to $28 million. → Could Truth API Become Trump Media’s First Meaningful Revenue Driver? President and CEO Michael Carrel said the quarter reflected “solid” performance and highlighted improving profitability. AtriCure recorded adjusted EBITDA of $27.3 million, up 78% from $15.4 million a year earlier. Net income was $9 million, compared with a net loss of $6.2 million in the prior-year quarter. Earnings per share and adjusted earnings per share were both $0.18, compared with a loss per share of $0.13 and an adjusted loss per share of $0.02 a year earlier. AtriCure’s U.S. business was supported by continued adoption of several newer devices, including CryoSphere MAX and cryoXT in pain management, AtriClip FLEX-Mini and PRO-Mini in appendage management, and the Encompass clamp in open ablation. → 3 Photonics Companies Making Quantum Tech Possible Pain management was the company’s fastest-growing franchise, with worldwide revenue up 27% in the quarter. U.S. pain management sales reached $27.1 million, up 27.8% year over year. Carrel said CryoSphere MAX remained a key driver, with the company continuing to add accounts while also seeing early traction in sternotomy procedures. During the question-and-answer portion of the call, Wirick said CryoSphere MAX represented about 75% of U.S. pain management revenue and that the company ended the quarter with “a little over 700 active accounts” in pain management. Carrel also pointed to early momentum for CryoXT, which is designed for use in amputation procedures. He said the product was included in a presentation at the Society for Vascular Surgery annual meeting and that early adopters are reporting improvements in patient experience and recovery. Management said CryoXT is expected to contribute more meaningfully to revenue in the second half of the year, though from a small base. → AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off Open ablation revenue increased 11% worldwide, led by the Encompass clamp. U.S. open ablation product sales were $40.9 million, up 12.1% year over year. Carrel said the company expects further adoption from a new Society of Thoracic Surgeons quality metric on concomitant AFib treatment, which he described as a potential long-term catalyst for surgical AFib ablation and left atrial appendage management. Appendage management revenue grew 14% in the quarter. U.S. sales of appendage management products increased 14.4% to $51.6 million, reflecting adoption of AtriClip FLEX-Mini and PRO-Mini devices. Carrel said the mini devices now account for 45% of appendage management revenue in their respective open and minimally invasive categories. The company’s minimally invasive ablation business continued to decline, contributing $6 million in U.S. revenue for the quarter. Carrel said the market remains focused on treating patients with pulsed field ablation, or PFA, catheters. He added that AtriCure still believes hybrid AFib therapy has a role in patients with longstanding persistent AFib, but said broader stabilization is needed before the franchise can return to growth. “We have seen referral patterns for hybrid procedures stabilize over the last several quarters in a small subset of accounts,” Carrel said. “However, we need to see this stabilization across a broader customer base before we can expect return to growth for this franchise.” Management emphasized progress in two major clinical trials that AtriCure says could expand the market for its cardiac surgery products. The BoxX-NoAF clinical study, which evaluates ablation and left atrial appendage management in cardiac surgery patients without a history of AFib, has surpassed 50% enrollment with more than 500 patients enrolled. AtriCure expects to complete enrollment of 960 patients by the end of 2026, ahead of its original plan, and anticipates data readouts in the first half of 2027. Carrel said the company sees a large unmet need in preventing post-operative AFib, noting that U.S. healthcare spending for the condition exceeds $2 billion annually. In response to an analyst question, he said the trial’s first endpoint is post-operative AFib measured 30 days after final enrollment, with a potential data presentation at a major medical meeting in 2027. He said the product is under a PMA pathway and that approval could take roughly a year after submission to the FDA. AtriCure is also continuing follow-up of more than 6,500 patients enrolled in the LeAAPS trial, which is studying the stroke reduction benefit of left atrial appendage management in cardiac surgery patients without AFib. Carrel said LeAAPS and BoxX-NoAF provide “multiple complementary paths for label expansion” and could be catalysts in the cardiac surgery market. AtriCure updated its 2026 outlook, now expecting revenue of $602 million to $610 million, representing growth of approximately 12.5% to 14% over 2025. The company expects growth to be led by pain management, appendage management and open ablation, while pressure persists in minimally invasive ablation and certain international markets. Wirick said AtriCure expects normal seasonal patterns in the second half, with third-quarter revenue down 1% to 2% sequentially from the second quarter, followed by a rebound in the fourth quarter. The company raised its adjusted EBITDA outlook to approximately $85 million to $89 million for 2026, implying an adjusted EBITDA margin of about 14% at the midpoint of guidance. AtriCure also reiterated its expectation for full-year net income and projected full-year earnings per share of approximately $0.05 to $0.13, with adjusted earnings per share of approximately $0.24 to $0.32. AtriCure ended the quarter with $167.8 million in cash and investments and generated approximately $22 million in cash during the quarter. Wirick said the company expects positive cash generation through the remainder of the year. During the call, analysts asked about new competitors in the appendage management market. Carrel said new entrants validate the market opportunity, but argued AtriCure has advantages in product innovation, clinical evidence and physician education. He said competitive trialing in the back half of the year is incorporated into the company’s guidance. Internationally, Wirick said Asia-Pacific weakness discussed in the prior quarter appeared transitory, while Europe saw softness in key markets including the U.K. and Germany. She said the company’s outlook incorporates continued pressure in certain markets. Carrel concluded that AtriCure’s double-digit revenue growth, margin improvement and profitability leave the company “well ahead” of its long-range plan, while ongoing trials could shape the company’s next decade. AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF. The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "AtriCure Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million Second Quarter 2026 cash generation of $21.6 million MASON, Ohio, July 23, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. "Our team delivered healthy growth and a significant step up in profitability in the second quarter," said Michael Carrel, President and Chief Executive Officer. "Our innovative technologies continue to prove their value, with strong growth in pain management bolstering our leading cardiac surgery portfolio. Meanwhile, we are rapidly advancing our BoxX-NoAF and LeAAPS clinical trials towards data readouts that we believe will inform and drive the next era of cardiac surgery patient care and growth for AtriCure. We remain confident in our ability to create lasting value for patients and shareholders." Second Quarter 2026 Financial Results Worldwide revenue for the second quarter 2026 was $153.6 million, an increase of 12.8% over second quarter 2025 revenue (12.4% on a constant currency basis). U.S. revenue was $125.6 million, an increase of $15.0 million or 13.6%, compared to the second quarter 2025. U.S. revenue growth was driven by sales of our cryoSPHERE® MAX™ probe for post-operative pain management, EnCompass® clamp in open ablation, and AtriClip FLEX-Mini® and AtriClip PRO-Mini® devices for appendage management. International revenue increased $2.5 million or 9.6% (7.1% on a constant currency basis) to $28.0 million, with growth in appendage management, open ablation, and pain management franchises. Gross profit for the second quarter 2026 was $118.6 million compared to $101.5 million for the second quarter 2025. Gross margin was 77.2% for the second quarter 2026, an increase of 269 basis points from the second quarter 2025, driven primarily by favorable product and geographic mix, along with manufacturing efficiencies. Income from operations for the second quarter 2026 was $9.7 million, compared to a loss from operations of $6.2 million for the second quarter 2025. Basic and diluted net income per share were $0.18 for the second quarter 2026, compared to basic and diluted net loss per share of $0.13 for the second quarter 2025. Adjusted EBITDA for the second quarter 2026 was $27.3 million, an increase of $11.9 million or 78% from the second quarter 2025. For the second quarter 2026, adjusted earnings per share was $0.18, compared to $0.02 adjusted loss per share for the second quarter 2025. Constant currency revenue, adjusted EBITDA and adjusted earnings (loss) per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release. 2026 Financial Guidance Full year 2026 revenue is projected to be approximately $602 million to $610 million, and management also projects full year 2026 adjusted EBITDA of approximately $85 million to $89 million. Full year 2026 net income per share is expected to be in the range of $0.05 to $0.13, and adjusted earnings per share is expected to be in the range of $0.24 to $0.32. Additionally, management expects continued positive cash generation for 2026. Conference Call AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss second quarter 2026 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure. Forward-Looking Statements Except for historical information, certain statements in this press release, including financial guidance and outlook, are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory-related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 19, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Use of Non-GAAP Financial Measures To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics. Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue for both management and investors. Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company’s core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired-in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and changes in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned "Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)" later in this release. Adjusted earnings (loss) per share is a non-GAAP measure which calculates the net income (loss) per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment. The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. View source version on businesswire.com: https://www.businesswire.com/news/home/20260723794845/en/ Contacts Angie WirickAtriCure, Inc.Chief Financial Officer(513) [email protected] Marissa BychGilmartin GroupInvestor Relations(415) [email protected]

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +500.00%. A quarter ago, it was expected that this medical device maker would post a loss of $0.07 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. AtriCure, which belongs to the Zacks Medical - Products industry, posted revenues of $153.6 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.39%. This compares to year-ago revenues of $136.14 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. AtriCure shares have lost about 15.3% since the beginning of the year versus the S&P 500's gain of 9.6%. While AtriCure has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for AtriCure was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.03 on $150.98 million in revenues for the coming quarter and $0.13 on $604.74 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Village Farms (VFF), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 10. This greenhouse operator is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -80%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Village Farms' revenues are expected to be $56.13 million, down 6.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AtriCure, Inc. (ATRC) : Free Stock Analysis Report Village Farms International, Inc. (VFF) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Worldwide revenue growth of 14% was fueled by an acceleration in the U.S. business, specifically driven by the AtriClip FLEX-Mini and cryoSPHERE MAX probe. The BoxX-NoAF clinical trial is tracking nearly one year ahead of schedule, with approximately 300 patients enrolled since Q4 2025, reflecting high surgeon engagement regarding postoperative Afib. Pain management remains the fastest-growing portfolio segment at 28% growth, with the cryoSPHERE MAX probe accounting for roughly 70% of these sales due to significant surgical time savings. Open ablation growth of 15% is being sustained by the EnCompass clamp, which continues to gain traction in both new and existing accounts as it approaches the four-year anniversary of its U.S. launch. Management attributes market share gains in appendage management to the small form factor and superior performance of the FLEX-Mini device against competitive offerings. The Society of Thoracic Surgeons' inclusion of concomitant Afib treatment as a quality metric is expected to serve as a durable tailwind for surgical ablation adoption starting in 2027. Full-year 2026 revenue guidance of $600 million to $610 million assumes continued strength in pain management, appendage management, and open ablation, partially offset by persistent headwinds in MIS ablation. Gross margins are expected to moderate in the second half of 2026 as expanded manufacturing facilities come online, increasing the manufacturing cost burden. Management expects to complete enrollment for the BoxX-NoAF trial by the end of 2026, leading to incremental R&D investment over the next three quarters. The company anticipates positive cash flow for the remainder of the year, with full-year cash generation expected to be moderately higher than in 2025. Launch of AtriClip FLEX-Mini and PRO-Mini in Europe is slated for later this year following recent CE Mark approval under EU MDR. International growth was tempered by ongoing uncertainty in the U.K. market and lumpy distributor ordering patterns in Asia. The MIS ablation franchise continues to face volume pressure as electrophysiologists trial multiple PFA catheters before referring patients for hybrid therapy. R&D spending will see a higher year-over-year increase in the second half of 2026 because 2025 comparisons only included LeAAPS enrollment costs for the first half of the year. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management has completed first-in-human procedures in Australia and is expanding to an additional 30 to 40 patients in Europe. The company expects to submit an IDE to the FDA later this year, with clinical trial enrollment likely beginning in 2027. Management noted that while Medtronic has entered the market, AtriCure has seen market share recovery following the peak of competitive trialing last fall. The strategy to defend market leadership relies on the FLEX-Mini's innovation and unique clinical evidence from the LeAAPS and BoxX trials that competitors lack. With enrollment potentially finishing by year-end 2026, management targets a late-breaker data presentation at a surgical congress in early 2027. The AATS meeting is cited as a likely venue for initial results, given the 30-day follow-up and data adjudication requirements. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.